Integer (NYSE:ITGR) Price Target Lowered to $140.00 at Benchmark

Integer (NYSE:ITGR) had its price objective reduced by Benchmark from $150.00 to $140.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other equities research analysts have also weighed in on ITGR. Truist Financial dropped their price objective on shares of Integer from $163.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, April 11th. Raymond James started coverage on Integer in a report on Friday, March 28th. They issued an “outperform” rating and a $145.00 price objective on the stock. KeyCorp decreased their target price on Integer from $154.00 to $145.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Finally, Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Integer has a consensus rating of “Moderate Buy” and an average target price of $145.56.

Integer Stock Up 1.6 %

Integer stock opened at $123.39 on Friday. Integer has a 1-year low of $104.93 and a 1-year high of $146.36. The business has a fifty day moving average price of $119.58 and a 200-day moving average price of $130.26. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The stock has a market capitalization of $4.31 billion, a price-to-earnings ratio of 36.72, a PEG ratio of 1.72 and a beta of 1.09.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. The business had revenue of $437.39 million during the quarter, compared to the consensus estimate of $428.51 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. Equities research analysts forecast that Integer will post 6.01 EPS for the current fiscal year.

Institutional Trading of Integer

A number of hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in shares of Integer in the fourth quarter worth about $38,073,000. Vaughan Nelson Investment Management L.P. purchased a new position in Integer during the first quarter worth approximately $33,337,000. Capital Research Global Investors grew its holdings in Integer by 16.0% in the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider’s stock valued at $186,960,000 after purchasing an additional 194,895 shares during the period. Artisan Partners Limited Partnership purchased a new stake in shares of Integer in the fourth quarter valued at approximately $22,775,000. Finally, GAMMA Investing LLC raised its stake in shares of Integer by 8,697.6% during the 1st quarter. GAMMA Investing LLC now owns 78,123 shares of the medical equipment provider’s stock worth $92,190,000 after buying an additional 77,235 shares during the period. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.